| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Istituto Nazionale per lo Studio e la Cura dei Tumori, Divisione di Oncologia Sperimentale E. Via Venezian 1, 20133 Milan, Italy [M. F., L. O., D. M., M. I. C., S. C.], and Medical Research Council Laboratory of Molecular Biology and Medical Research Council Centre for Protein Engineering, Hills Road, Cambridge CB2 2QH, United Kingdom [A. G., G. W.]
The display of repertoires of human antibody (Ab) fragments on filamentous phages and selection by binding of the phage to antigen (Ag) have provided a ready means of deriving human Ab against purified Ag. However, it has been more difficult to obtain phage Ab against an individual Ag of a complex mixture, such as cell surface Ag. Using the technique of "guided selection," we generated human Ab against the high-affinity folate-binding protein (FBP), a cell surface Ag that is overexpressed in many human ovarian carcinomas. The guiding Ab template was provided by the light chain of mouse monoclonal Ab Mov19 (Kaff, 108 M-1) directed against FBP; this was paired with repertoires of human heavy chains displayed on phages, and the hybrid Ab fragments were selected by binding to an ovarian carcinoma cell line (OVCAR3). The selected human heavy chains were then paired with repertoires of human light chains. Further panning led to the isolation of a human Fab fragment, C4, with a binding affinity of 0.2 x 108 M-1. This was highly specific for FBP, as demonstrated by ELISA and flow cytometry data and by immunoprecipitation of the relevant molecule from the cell surface of ovarian carcinoma cells. Moreover, C4 targeted the same or a closely related epitope of the Ag, as did the template rodent monoclonal Ab Mov19. These results suggest the usefulness of guided selection as a simple means to deriving human Ab against cell surface Ag for which a rodent Ab is available.
1 This work was supported by the Associazione Italiana per la Ricerca sul Cancro/Fondazione Italiana per la Ricerca sul Cancro, Progetto Finalizzato RC, PF Applicazioni Cliniche della Ricerca Oncologica-Consiglio Nazionale delle Ricerche, Italian Health Ministry finalized program, and Italy-United States program "Therapy of Tumors."
2 Present address: Policlinico San Matteo Medicina Interna ed Oncologia Medica, 27100 Pavia, Italy.
3 To whom requests for reprints should be addressed, at Division of Experimental Oncology E, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy. Phone: (39-2) 239-0567; Fax: (39-2) 236-2692.
Received 8/11/97. Accepted 1/ 5/98.
This article has been cited by other articles:
![]() |
T. Heitner, N. Satozawa, K. Mclean, D. Vogel, R. R. Cobb, B. Liu, M. Mahmoudi, S. Finster, B. Larsen, Y. Zhu, et al. Obligate Multivalent Recognition of Cell Surface Tomoregulin following Selection from a Multivalent Phage Antibody Library J Biomol Screen, December 1, 2006; 11(8): 985 - 995. [Abstract] [PDF] |
||||
![]() |
M. H. Kershaw, J. A. Westwood, L. L. Parker, G. Wang, Z. Eshhar, S. A. Mavroukakis, D. E. White, J. R. Wunderlich, S. Canevari, L. Rogers-Freezer, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res., October 15, 2006; 12(20): 6106 - 6115. [Abstract] [Full Text] [PDF] |
||||
![]() |
E.-M. Krinner, J. Hepp, P. Hoffmann, S. Bruckmaier, L. Petersen, S. Petsch, L. Parr, I. Schuster, S. Mangold, G. Lorenczewski, et al. A highly stable polyethylene glycol-conjugated human single-chain antibody neutralizing granulocyte-macrophage colony stimulating factor at low nanomolar concentration Protein Eng. Des. Sel., October 1, 2006; 19(10): 461 - 470. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. B. Jensen, O. N. Jensen, P. Ravn, B. F. C. Clark, and P. Kristensen Identification of Keratinocyte-specific Markers Using Phage Display and Mass Spectrometry Mol. Cell. Proteomics, February 1, 2003; 2(2): 61 - 69. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Itoh, K. Inoue, T. Tezuka, H. Tada, Y. Hashimoto, T. Masuko, and T. Suzuki Molecular Structural and Functional Characterization of Tumor Suppressive Anti-ErbB-2 Monoclonal Antibody by Phage Display System J. Biochem., February 1, 2003; 133(2): 239 - 245. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |